Pipeline

Internal Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Etrasimod
GI
ELEVATE UC 52

95%

ELEVATE UC 12

95%

GLADIATOR UC

73%

CULTIVATE (CD)

95%

VOYAGE (EoE)

73%

Derm
ADVISE – Atopic Dermatitis (AD)

95%

Alopecia Areata (AA)

73%

CR
Controlled Release

58%

Olorinab
GI
CAPTIVATE IBS-C/D

73%

APD418
CV
Acute HF (AHF)

73%

Research Partnerhip Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Project Cabrillo
Early Stage Immune & Inflammatory Platform w/ Beacon
Target 1

20%

Target 2

15%

Additional Targets

15%

Partnered / Licensed Programs Early Research Pre-Clinical Phase 1 Phase 2 Phase 3
Ralinepag
UTHR
PAH

95%

Multiple Assets
Longboard
LP352

50%

LP143

25%

LP659

20%

Additional Targers

15%

Undisclosed Orphan GPCR
BI
CNS

30%

Program Indication Phase
Internal Programs
Etrasimod
ELEVATE UC 52 Ph3
ELEVATE UC 12 Ph3
GLADIATOR UC Ph2b Planning
CULTIAVTE (CD) Ph2/3
VOYAGE (EoE) Ph2b Planning
ADVISE – Atopic Dermatitis (AD) Ph3 Planning
Alopecia Areata (AA) Ph2 Planning
Controlled Release (CR) Ph1
Olorinab
CAPTIVATE (IBS-C/D)) Ph2b
APD418
Decompensated HF (DHF) Ph2
Research Partnerhip
Project Cabrillo
Target 1 Early Research
Target 2 Early Research
Additional Targets Early Research
Partnered / Licensed Programs
Ralinepag
PAH Ph3
Longboard
LP352 Ph1
LP143 Early Research
LP659 Early Research
Additional Targets Early Research
Undisclosed Orphan GPCR
CNS PC

Expanded Access Policy

Last updated as of 10/24/2020